Microdissection Testicular Sperm Extraction
Conditions
Keywords
Nonobstructive Azoospermia, oligoasthenoteratozoospermia, intracytoplasmic sperm injection, In vitro fertilization, cryptozoospermia
Brief summary
This is a retrospective study to assess outcomes of micro-TESE performed 24 or 48 hours before oocyte retrieval and ICSI.
Detailed description
This retrospective study evaluates patients undergoing ICSI following micro-TESE. Participants are assigned to two groups based on the interval between sperm extraction and oocyte retrieval (24 vs. 48 hours). Clinical and embryological outcomes from the first embryo transfer will be assessed.
Interventions
None listed
Sponsors
Clinique Ovo
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men who underwent a micro-TESE at the OVO clinic from June 2015 to January 2025. * Patients with non-obstructive azoospermia (NOA), (absence of spermatozoa in multiple semen analyses) * Patients with cryptozoospermia, (presence of a small number of spermatozoa detectable only after semen centrifugation) * Patients with oligoasthenoteratozoospermia (OAT), (sperm concentration of less than 15 million/mL, reduced motility and abnormal morphology)
Exclusion criteria
* Patients who did not have any sperm noted following micro-TESE * Use of donor sperm or oocytes * Frozen sperm or oocytes * Same day oocyte retrieval and sperm extraction * Reversible cause of cryptozoospermia (i.e presence of a varicocele, febrile illness, or recent toxin exposure) Partial genital tract obstruction (i.e post-vaso-vasostomy, post-vasoepididymostomy, and low volume cryptozoospermia with ejaculatory duct obstruction)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of live births following ICSI with micro-TESE either 24 or 48 hours prior to oocyte retrieval | For IVF performed from June 2015 to January 2025 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of fertilized oocytes with two pronuclei (2PN) | For IVF performed from June 2015 to January 2025 |
| Percentage of usable blastocyst (defined as frozen and transferred blastocysts) | For IVF performed from June 2015 to January 2025 |
| Pregnancy rate based on positive β-hCG | For IVF performed from June 2015 to January 2025 |
Countries
Canada
Outcome results
None listed